Fenofibrate-induced Renal Dysfunction, Yes or No?

Overview

Journal J Res Med Sci

Specialty General Medicine

Date 2020 Jun 26

PMID 32582345

Citations 10

Authors

Fatemeh Emami

Amirali Hariri

Mohammad Matinfar

Mehdi Nematbakhsh

Affiliations

Soon will be listed here.

Abstract

In the treatment process of hypertriglyceridemia and diabetic nephropathy in type 2 diabetes, fenofibrate (FEN) is a well-known medication. FEN is from fibrate class drugs that using orally; however, as a side effect, it is associated with serum creatinine level increasing. The aim of this review was to determine the real effect of FEN therapy on renal functions based on both experimental and clinical studies. For this review, using the keywords of "fenofibrate" and "renal" and "function," a variety of sources of information banks, including PubMed, Google Scholar, and Scopus, were used, and the published articles were considered and interpreted. Followed by searching in databases, 45 articles were collected. After screening these articles, based on the study source, they were devided into two parts: 23 articles on animal experiments and 22 articles clinical experiments. Based on this information, it seems that the protective mechanism of FEN is related to vascular endothelial functions. The increased creatinine by FEN is related to different sensitivities to FEN effects caused by a polymorphism in different patients. In patients with normal renal function, follow-up of serum creatinine would be necessary after FEN, but the discontinuation of FEN is not recommended. In addition, in diabetic patients with hypertriglyceridemia, FEN treatment would be suggested for protecting the kidney from diabetes-induced renal injury.

Citing Articles

Future Directions in Diabetic Retinopathy Treatment: Stem Cell Therapy, Nanotechnology, and PPARα Modulation.

Kapa M, Koryciarz I, Kustosik N, Jurowski P, Pniakowska Z J Clin Med. 2025; 14(3).

PMID: 39941353 PMC: 11818668. DOI: 10.3390/jcm14030683.

Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023.

Katsiki N, Filippatos T, Vlachopoulos C, Panagiotakos D, Milionis H, Tselepis A Atheroscler Plus. 2024; 55:74-92.

PMID: 38425675 PMC: 10901915. DOI: 10.1016/j.athplu.2024.01.004.

Fenofibrate reduces glucose-induced barrier dysfunction in feline enteroids.

Crawford C, Beltran A, Castillo D, Matloob M, Uehara M, Quilici M Sci Rep. 2023; 13(1):22558.

PMID: 38110453 PMC: 10728136. DOI: 10.1038/s41598-023-49874-9.

Effects of Fenofibrate and Gemfibrozil on Kynurenic Acid Production in Rat Kidneys In Vitro: Old Drugs, New Properties.

Zakrocka I, Kocki T, Urbanska E, Zaluska W Life (Basel). 2023; 13(11).

PMID: 38004294 PMC: 10672417. DOI: 10.3390/life13112154.

Can coenzyme Q10 alleviate the toxic effect of fenofibrate on skeletal muscle?.

El-Bassouny D, Mansour A, Ellakkany A, Ayuob N, AbdElfattah A Histochem Cell Biol. 2023; 160(2):147-158.

PMID: 37270716 PMC: 10386954. DOI: 10.1007/s00418-023-02205-5.

References

Tanaka Y, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, Sakaguchi M . Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int. 2011; 79(8):871-82. DOI: 10.1038/ki.2010.530. View

Eddy A . Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol. 2002; 283(2):F209-20. DOI: 10.1152/ajprenal.00032.2002. View

Sohn M, Kim K, Uddin M, Lee G, Hwang I, Kang H . Delayed treatment with fenofibrate protects against high-fat diet-induced kidney injury in mice: the possible role of AMPK autophagy. Am J Physiol Renal Physiol. 2016; 312(2):F323-F334. DOI: 10.1152/ajprenal.00596.2015. View

Bruno C, Schapiro J, Saberi P . An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature. J Int Assoc Physicians AIDS Care (Chic). 2011; 10(4):219-22. PMC: 3222949. DOI: 10.1177/1545109711404945. View

Hottelart C, El Esper N, Rose F, Achard J, Fournier A . Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002; 92(3):536-41. DOI: 10.1159/000064083. View

Kazumi T, Hirano T, Yoshino G, For The Fenofibrate Study Group . Effects of fenofibrate on albuminuria in patients with hypertriglyceridemia and/or hyperuricemia: a multicenter, randomized, double-blind, placebo-controlled, crossover study. Curr Ther Res Clin Exp. 2014; 64(7):434-46. PMC: 4053029. DOI: 10.1016/S0011-393X(03)00127-9. View

Danis R, Akbulut S, Ozmen S, Arikan S . Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review. Case Rep Med. 2010; 2010. PMC: 2926591. DOI: 10.1155/2010/537818. View

Zhao X, Quigley J, Yuan J, Wang M, Zhou Y, Imig J . PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am J Physiol Heart Circ Physiol. 2006; 290(6):H2187-95. DOI: 10.1152/ajpheart.00937.2005. View

Yaribeygi H, Mohammadi M, Rezaee R, Sahebkar A . Fenofibrate improves renal function by amelioration of NOX-4, IL-18, and p53 expression in an experimental model of diabetic nephropathy. J Cell Biochem. 2018; 119(9):7458-7469. DOI: 10.1002/jcb.27055. View

10.

Wei Y, Lin D, Kemp R, Yaddanapudi G, Nasjletti A, Falck J . Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways. J Gen Physiol. 2004; 124(6):719-27. PMC: 2234027. DOI: 10.1085/jgp.200409140. View

11.

Hou X, Shen Y, Li C, Wang F, Zhang C, Bu P . PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity. Biochem Biophys Res Commun. 2010; 394(3):653-9. DOI: 10.1016/j.bbrc.2010.03.043. View

12.

Forsblom C, Hiukka A, Leinonen E, Sundvall J, Groop P, Taskinen M . Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care. 2009; 33(2):215-20. PMC: 2809252. DOI: 10.2337/dc09-0621. View

13.

Zhou Y, Kong X, Zhao P, Yang H, Chen L, Miao J . Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injury. Kidney Int. 2011; 79(12):1302-11. DOI: 10.1038/ki.2011.17. View

14.

Ovcharenko E, Hansen M, Goltsman I, Abu-Saleh N, Abassi Z, Walsh K . Peroxisome proliferator-activated receptor alpha and alpha/gamma agonists do not cause impairment in renal function in the rat. Nephron Physiol. 2010; 115(3):p21-30. DOI: 10.1159/000314541. View

15.

Hong Y, Lim J, Kim M, Kim T, Kim Y, Yang K . Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1α in db/db mice. PLoS One. 2014; 9(5):e96147. PMC: 4011795. DOI: 10.1371/journal.pone.0096147. View

16.

Helmy M, Helmy M, El-Mas M . Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs. PLoS One. 2015; 10(11):e0142303. PMC: 4633146. DOI: 10.1371/journal.pone.0142303. View

17.

Zhao Y, Weir M, Manno M, Cordy P, Gomes T, Hackam D . New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med. 2012; 156(8):560-9. DOI: 10.7326/0003-4819-156-8-201204170-00003. View

18.

Mychaleckyj J, Craven T, Nayak U, Buse J, Crouse J, Elam M . Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care. 2012; 35(5):1008-14. PMC: 3329840. DOI: 10.2337/dc11-1811. View

19.

Balakumar P, Varatharajan R, Nyo Y, Renushia R, Raaginey D, Oh A . Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacol Res. 2014; 90:36-47. DOI: 10.1016/j.phrs.2014.08.008. View

20.

Chung H, Lim J, Kim M, Shin S, Chung S, Choi B . High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α pathway. Nephrol Dial Transplant. 2011; 27(6):2213-25. DOI: 10.1093/ndt/gfr613. View